NCT05365438

Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Effect of Atorvastatin and Omega 3 Combination Therapy on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined Dyslipidemia

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 105 (estimated)
• Sponsor: Seoul National University Bundang Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized controlled study to assess the effect of atorvastatin and omega 3 combination therapy compared with atorvastatin and ezetimibe combination therapy in Korean T2DM patients with asymptomatic atherosclerosis.

Detailed description

In patients with type 2 diabetes with atherosclerotic combined dyslipidemia, the effect of atorvastatin and omega 3 combination on the progression of carotid intima media thickness and carotid artery plaque will be evaluated by 3D carotid ultrasound.

Conditions

• Dyslipidemias
• Atherosclerosis
• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	Omega 3-Atorvastatin	Atmeg 2 capsules with 1 pack of Omethyl cutielet
DRUG	Omega 3-Atorvastatin	Atmeg 2 capsules
DRUG	Atorvastatin-Ezetimibe	ezetimibe/atorvastatin 10/20 mg

Timeline

• Start date: 2022-10-01
• Primary completion: 2025-12-31
• Completion: 2026-12-31
• First posted: 2022-05-09
• Last updated: 2024-05-01

Locations

1 site across 1 country: South Korea